Detalles de la búsqueda
1.
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
J Formos Med Assoc
; 119(12): 1817-1826, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094063
2.
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Br J Clin Pharmacol
; 84(6): 1156-1169, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29381826
3.
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.
J Formos Med Assoc
; 117(4): 326-331, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28499641
4.
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Oncologist
; 22(9): 1075-1083, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28507206
5.
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study.
J Clin Oncol
; : JCO2401001, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857463
6.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
J Clin Oncol
; 41(35): 5363-5375, 2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37689979
7.
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.
J Magn Reson Imaging
; 36(2): 387-96, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22517425
8.
Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors.
JTO Clin Res Rep
; 3(11): 100405, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325153
9.
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
J Thorac Oncol
; 17(3): 411-422, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34801749
10.
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan.
JTO Clin Res Rep
; 2(2): 100140, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589991
11.
The Role of Interleukin 1ß in the Pathogenesis of Lung Cancer.
JTO Clin Res Rep
; 1(1): 100001, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589908
12.
Reply to Y. Yu et al.
J Clin Oncol
; 42(17): 2108-2110, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38569121
13.
Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study.
Clin Lung Cancer
; 20(6): e609-e618, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31377141
14.
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Clin Lung Cancer
; 19(4): e465-e479, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29653820
15.
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
J Thorac Oncol
; 16(9): 1426-1428, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34425993
16.
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 17(5): e103-e112, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236385
17.
Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?
J Thorac Oncol
; 15(3): 305-307, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32093849
18.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
J Thorac Oncol
; 10(5): 793-799, 2015 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25668120
Resultados
1 -
18
de 18
1
Próxima >
>>